SCHEMBL187849

SCHEMBL187849

COC(=O)C(NC(=O)OCc1ccccc1)P(=O)(OC)OC

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KYNU Q16719 1/20 0.62
ELANE P08246 2/20 0.57
TRPM8 Q7Z2W7 1/20 0.53
ALDH1A1 P00352 1/20 0.53
ALOX15 P16050 1/20 0.53
KLK1 P06870 1/20 0.52
CTRB1 P17538 2/20 0.51
ATM Q13315 2/20 0.51
PRTN3 P24158 2/20 0.51
TP53 P04637 1/20 0.50
F2 P00734 1/20 0.49
PLAU P00749 1/20 0.49
PLAT P00750 1/20 0.49
CTSK P43235 2/20 0.49
TACR1 P25103 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29678939 1.00 KYNU (0.62) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL269404 1.00 KYNU (0.62) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL19410220 0.96 KYNU (0.57) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL13435790 0.93 KYNU (0.57) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL535707 0.93 KYNU (0.57) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL1110994 0.92 KYNU (0.56) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL13798138 0.92 KYNU (0.56) KYNUELANETRPM8ALDH1A1ALOX15
Lithium Ion SCHEMBL1110992 0.91 KYNU (0.55) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL13798136 0.90 KYNU (0.52) KYNUELANETRPM8ALDH1A1ALOX15
SCHEMBL29112134 0.89 KYNU (0.56) KYNUELANETRPM8ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137643-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL SOC DES PRODUITS NESTLE S A (CH) 2026-05-21 US claimed
US-12539288-B2 Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-02-03 US claimed
US-20250281438-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL SOCIETE DES PRODUITS NESTLE S.A. (CH) 2025-09-11 US claimed
EP-4440563-A1 COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL Société des Produits Nestlé S.A. (CH) 2024-10-09 EP claimed
US-20240100006-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF SOCIETE DES PRODUITS NESTLE S.A. (CH) 2024-03-28 US claimed
US-20240091186-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR SOCIETE DES PRODUITS NESTLE S.A. (CH) 2024-03-21 US claimed
EP-4262776-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL Société des Produits Nestlé S.A. (CH) 2023-10-25 EP claimed
EP-4259120-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF Société des Produits Nestlé S.A. (CH) 2023-10-18 EP claimed
US-20230172232-A1 COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL Société des Produits Nestlé S.A. (CH) 2023-06-08 US claimed
WO-2023100077-A1 COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL SOCIETE DES PRODUITS NESTLE SA (CH) 2023-06-08 WO claimed
WO-2022128870-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL Société des Produits Nestlé S.A. (CH) 2022-06-23 WO claimed
WO-2022122730-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF Société des Produits Nestlé S.A. (CH) 2022-06-16 WO claimed
US-6398857-B1 ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS XEROX CORPORATION 2002-06-04 US claimed
US-6395077-B1 INKS WITH BENZOYLBENZOIC ACID AND COLORS XEROX CORPORATION 2002-05-28 US claimed
JP-9056376-A None JP disclosed
US-20260137643-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL SOC DES PRODUITS NESTLE S A (CH) 2026-05-21 US disclosed
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 US disclosed
WO-1995013262-A1 SUBSTITUTED PHENYL COMPOUNDS RHONE-POULENC RORER LIMITED (GB) 1995-05-18 WO disclosed
WO-1995010517-A1 INDOLE DERIVATIVES AS NMDA ANTAGONISTS GLAXO WELLCOME S.P.A. (IT) 1995-04-20 WO disclosed
JP-H00956376-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539288-B2 Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol LIPC, GGT1, TGM2 KYNU 363/4885ELANE 450/4885TRPM8 3772/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 KYNU 4159/4885ELANE 2927/4885TRPM8 4633/4885
US-20260137643-A1 COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL LIPC, GGT1, TGM2 KYNU 339/4885ELANE 442/4885TRPM8 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.